卵巢癌及卵巢交界性肿瘤中的循环钙卫蛋白
Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary.
作者信息
Ødegaard Elin, Davidson Ben, Elgaaen Bente Vilming, Fagerhol Magne K, Engh Vibeke, Onsrud Mathias, Staff Anne Cathrine
机构信息
Department of Obstetrics and Gynecology, Ulleval University Hospital, Oslo, Norway.
出版信息
Am J Obstet Gynecol. 2008 Apr;198(4):418.e1-7. doi: 10.1016/j.ajog.2007.10.792. Epub 2008 Feb 1.
OBJECTIVE
Recent studies indicate that circulating calprotectin may serve as a biomarker in some cancers. We investigated whether this is the case for ovarian neoplasms.
STUDY DESIGN
Calprotectin was analyzed with an enzyme-linked immunosorbent assay in EDTA-plasma collected prior to surgery from women with ovarian carcinomas (n = 89), borderline ovarian tumors (BOT, n = 39), and benign ovarian tumors (n = 71). Serum CA 125 was analyzed in the same study population.
RESULTS
Median plasma calprotectin concentration was elevated in ovarian carcinoma, compared with controls, as well as compared with BOT (both P < .001). A positive correlation was found between CA 125 and calprotectin concentrations in ovarian carcinoma. Receiver operating characteristic curves demonstrated a larger area under the curve for CA 125 (0.85) as compared with calprotectin (0.70).
CONCLUSION
Plasma calprotectin is elevated in invasive ovarian cancer, but when used as a tumor marker, it is inferior to CA 125.
目的
近期研究表明，循环中的钙卫蛋白可能在某些癌症中作为生物标志物。我们调查了卵巢肿瘤是否也是这种情况。
研究设计
采用酶联免疫吸附测定法分析了术前从患有卵巢癌（n = 89）、卵巢交界性肿瘤（BOT，n = 39）和卵巢良性肿瘤（n = 71）的女性收集的乙二胺四乙酸（EDTA）血浆中的钙卫蛋白。在同一研究人群中分析了血清CA 125。
结果
与对照组以及与BOT相比，卵巢癌患者血浆钙卫蛋白浓度中位数均升高（均P <.001）。在卵巢癌中，发现CA 125与钙卫蛋白浓度之间呈正相关。受试者工作特征曲线显示，与钙卫蛋白（0.70）相比，CA 125的曲线下面积更大（0.85）。
结论
侵袭性卵巢癌患者血浆钙卫蛋白升高，但用作肿瘤标志物时，其性能不如CA 125。
Zotero 插件